Hometown healthcare heroes at Massey
In the May 2013 issue of Our Health Richmond magazine, Massey staff members Donna Cox, John McCarty, Ellie Coyne and Mandy Gatesman were recognized as “Hometown Healthcare Heroes.” The winners were selected by a panel of community members based on their community involvement, dedication to the field of healthcare and commitment to improve services and procedures.
Clinical trials seek to enhance the treatments and quality of life for melanoma patients
Andrew Poklepovic, M.D., is leading two clinical trials for melanoma at Massey. One trial studies the effects of investigational drug ipilimumab, a biological agent that has been shown to have anti-tumor activity in advanced (stage 4) melanoma, versus FDA-approved drug interferon alpha-2b, which has been shown to reduce the risk of melanoma returning in a portion of patients. The other clinical trial is a phase 2 study that tests a combination therapy of experimental drugs on patients who have a genetic mutation called B-Raf gene (BRAF V600E).
From head to toe: how to perform a skin self-exam
Skin cancer is the most common type of cancer, accounting for nearly half of all cancers in the United States. Skin cancer is also treatable when found early. Here are step-by-step instructions on how to perform a skin self-exam, which is best done in a well-lit room in front of a full-length mirror. Consider asking another person to help you with the exam, especially for those hard-to-see areas like your back and scalp.
Answers to burning questions about sunscreen
One way to determine what SPF is best for you is by using the following equation: Minutes to burn without sunscreen x SPF number = maximum sun exposure time. Sunscreen should be applied at least 30 minutes before going out into the sun in order to allow it time to absorb into your skin. It should also be applied generously and at least every two hours, or more often if you are swimming or perspiring.
Prostate cancer trial aims to reduce radiation treatments
VCU Massey Cancer Center has opened a Phase I clinical trial testing an innovative radiation therapy for patients with early stage prostate cancer that has the potential to drastically reduce treatment time. In comparison to the standard schedule of eight weeks of daily external beam radiation therapy, the new technique requires just four treatments, administered twice in the first week and twice in the fourth week.